What is King Pharmaceuticals's D&A?

King Pharmaceuticals (KG) reported D&A of $9K in Q1 2026.

How has King Pharmaceuticals's D&A changed year-over-year?

King Pharmaceuticals's D&A decreased by 50.0% year-over-year, from $18K to $9K.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

King Pharmaceuticals KG D&A

D&A at other companies

KKR & Co.KKR

-$77.39M-44.3%

Skyward Specialty Insurance Group, Inc.SKWD

$883.75K+5.3%

Selective Insurance GroupSIGI

$9.61M+5.3%

Verisk Analytics, Inc.VRSK

$69.9M+3.7%

W.R. BerkleyWRB

-$15.47M-58.0%

Tiptree Inc.TIPT

——

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-71.3%

Enterprise value$184.93M-52.3%

P/E1.2×—

P/S1.6×-27.7×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAmortizationAndAccretionNet.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's D&A?: King Pharmaceuticals (KG) reported D&A of $9K in Q1 2026.
How has King Pharmaceuticals's D&A changed year-over-year?: King Pharmaceuticals's D&A decreased by 50.0% year-over-year, from $18K to $9K.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.